You are here: Home » Companies ¬Ľ News
DoT seeks 'frontline' tag for telco field force amid Covid-19 pandemic
icon-arrow-left
Huawei Technologies seeks reboot after losing out on 5G spectrum trials
Business Standard

Eli Lilly signs licensing pact with Cipla, Sun, Lupin for Covid-19 drug

Olumiant, or Baricitinib, is an oral drug developed by US biopharmaceutical major, Incyte Corporation, and licensed to Eli Lilly

Topics
Eli Lilly | Coronavirus | Indian pharma companies

Sohini Das  |  Mumbai, 



Eli Lilly logo is shown on one of the company's offices in San Diego, California. Photo: Reuters
Eli Lilly logo is shown on one of the company's offices in San Diego, California. Photo: Reuters

US pharma giant has issued royalty-free, non-exclusive voluntary licences to three Indian drug makers – Cipla, Sun Pharmaceuticals and Lupin – to manufacture and distribute Baricitinib, which is being used to treat Covid-19.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Tue, May 11 2021. 00:53 IST

RECOMMENDED FOR YOU

.